* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hisamitsu Pharmaceutical Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hisamitsu Pharmaceutical Co Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hisamitsu Pharmaceutical Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Hisamitsu Pharmaceutical Co's Days Payable falls into.
Hisamitsu Pharmaceutical Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hisamitsu Pharmaceutical Co (FSE:4530) has a Days Payable of 60.19 as of Nov. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Hisamitsu Pharmaceutical Co and its competitors. This is 11% above median its historical median of 54.39. Over the past decade, Hisamitsu Pharmaceutical Co's Days Payable has ranged from 51.50 to 73.10. According to the industry distribution chart, Hisamitsu Pharmaceutical Co ranks #644 out of 923 companies in the Drug Manufacturers industry, placing it in the top 69.8%.
Is Hisamitsu Pharmaceutical Co's Days Payable too high?
Hisamitsu Pharmaceutical Co's current Days Payable of 60.19 is 11% above median its 10-year median of 54.39. Over the past 10 years, this metric has ranged from a low of 51.50 to a high of 73.10. The Drug Manufacturers industry median Days Payable is 90.98. Hisamitsu Pharmaceutical Co's value of 60.19 is 33.8% below this industry median. Based on the distribution chart, Hisamitsu Pharmaceutical Co ranks #644 out of 923 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Hisamitsu Pharmaceutical Co ranks #644 out of 923 companies for Days Payable. This places Hisamitsu Pharmaceutical Co in the lower half of its industry. The industry median Days Payable is 90.98. Hisamitsu Pharmaceutical Co's value of 60.19 is 33.8% below this benchmark. Historically, Hisamitsu Pharmaceutical Co's own Days Payable has ranged from 51.50 to 73.10 over the past decade. While the company's 10-year median is 54.39 vs. the industry median of 90.98, Hisamitsu Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hisamitsu Pharmaceutical Co's current Days Payable of 60.19 is 33.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Hisamitsu Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hisamitsu Pharmaceutical Co's current Days Payable is 60.19, which is 11% above median its own 10-year median of 54.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Hisamitsu Pharmaceutical Co (FSE:4530) has a current Days Payable of 60.19. The stock's GF Value™ is 円3,237.07, compared to a current price of 円3,975.00 — trading 22.8% above its estimated fair value. The current Days Payable is 60.19, which is 11% above median its 10-year median of 54.39 and 33.8% below the Drug Manufacturers industry median of 90.98. Hisamitsu Pharmaceutical Co's overall GF Score™ is 89/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (FSE:4530), the current Days Payable is 60.19 as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hisamitsu Pharmaceutical Co (FSE:4530) Overvalued in 2026?
Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円3,975.00 is trading 22.8% above its estimated GF Value™ of 円3,237.07.
Key valuation signals for FSE:4530:
Days Payable: 60.19 (11% above median its 10-year median of 54.39)
GF Value™: 円3,237.07 vs. price of 円3,975.00 (22.8% above fair value)
Industry Position: 33.8% below the Drug Manufacturers median (#644 of 923)
No single metric tells the full story. See the FSE:4530 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
89GF Score
Get the complete analysis for FSE:4530
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FSE:4530 has been successfully added to your 
